Norway has been invited to participate in a phase III randomized double blind placebo controlled trial of a new rotavirus vaccine in India with the Department of Biotechnology (DBT) in India and the international nonprofit organization PATH (http://www.path.org). Norwegian scientist and research groups are invited to participate in collaborative activities, which will be coordinated through the Norwegian Institute of Public Health, and supported by the Research Council of Norway (RCN). Potential collaborators are invited to attend a meeting in Oslo on September 16^th 2009, at the Norwegian Research Council, Stensberggata 26, from 10:00 to 13:00, where possible modes of collaboration will be discussed. Please see attached document.

 Invitation.pdf  

tter.pdf

For information regarding this project, possible modes of collaboration, and the process ahead, please contact:  Tor Strand, project coordinator, The Norwegian Institute of Public Health ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it tel. 90 97 10 86) or Kårstein Måseide, GLOBVAC programme coordinator, The Research Council of Norway ( This e-mail address is being protected from spambots. You need JavaScript enabled to view it , tel. 22 03 74 57)

To register for the meeting, please send an e-mail to Solfrid Johansen, Norwegian Institute of Public Health at This e-mail address is being protected from spambots. You need JavaScript enabled to view it by 10 September with your name, institute, e-mail address and telephone number.